Open Access<p>A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects</p>
Author(s) -
Chao Liu,
Hong Lü,
Fangyan Yuan,
Weili Chen,
Hongtao Xu,
Hui Li,
ChengPang Hsu,
Ogo Egbuna,
Jianhua Wu,
Clapton Dias,
Bassam Abosaleem,
Jitesh Rana,
Maria Laura Monsalvo,
Xuening Li,
Yu Zhang
Publication year - 2019
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1438
DOI - 10.2147/cpaa.s208033
Subject(s) - evolocumab , tolerability , pharmacodynamics , cmax , placebo , pharmacokinetics , medicine , pcsk9 , pharmacology , adverse effect , gastroenterology , endocrinology , cholesterol , lipoprotein , alternative medicine , ldl receptor , apolipoprotein a1 , pathology
Evolocumab is a human monoclonal antibody that reduces circulating low-density lipoprotein cholesterol (LDL-C) by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Data on evolocumab pharmacokinetics and pharmacodynamics are derived mostly from Caucasian populations. The objectives of this study were to characterize the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of evolocumab in healthy Chinese subjects.